Gazda, MD, assistant professor in the department of internal medicine at University of Texas Southwestern Medical Center, and colleagues wrote in the study background
The FDA declared both the semaglutide and tirzepatide shortages resolved in late 2024 and early 2025, and compounding pharmacies were required to stop producing essentially identical copies by mid-2025
2023;doi:10.1136/ard-2023-223845
385,387 PF1801 displays its anti-inflammatory effects by lowering levels of inflammatory mediators such as TNF, IL-6, and HMGB1, and enhances the cells antioxidant capability by upregulating molecules like Nfe2l2, Hmox1, Gclm, and Nqo1, which further improves cellular defense against oxidative stress and protects them from further damage
Liposome L-glutachion yeast extract 34.22% (from the Netherlands/yeast extract, lecithin), pullulan, vitamin C, enzyme-treated stevia, lemon juice powder [dextrin, lemon juice (100% made in the United States), arabic gum, citric acid, flavoring], hydroxypropylmethylcellulose, milk thistle extract powder (made in the United States), -cyclodextrin, glycerin, flavoring (natural lemon), other edible oil and vegetable products, vitamin E, giza yellow pigment, polysorbate 80, L-cysteine hydrochloride, citric acid, modified starch milk